1) Plasminogen activator inhibitors-2(PAI-2)
纤维酶原激活抑制物-2
2) plasminogen activator inhibitor-1
纤溶酶原激活物抑制物
1.
Objective:To analyze the plasma levels of tissue plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1) in patients with coronary heart disease(CHD) and to assess its clinical implications.
方法:回顾性分析本院222例冠心病患者血浆组织型纤溶酶原激活物(t-PA)及纤溶酶原激活物抑制物-1(PAI-1)水平。
2.
ObjectiveTo evaluate the plasminogen activator system (plasminogen activator inhibitor-1 and tissue plasminogen activator) in women with PCOS and compared in groups .
目的:探讨纤溶酶原激活物抑制物-1(PAI-1)和组织型纤溶酶原激活物(t-PA)的高低与多囊卵巢综合征(polycystic ovary syndrome, PCOS)患者病变发展之间的关系以探寻一较好的监测指标。
3.
Objective To investigate the role of rosiglitazone in improving blood lipids and proteinuria in rats with Type 2 diabete,and the effect of rosiglitazone on expressions of plasminogen activator inhibitor-1 in kidney of streptozotocin-diabetic rats.
目的研究罗格列酮对2型糖尿病大鼠血糖血脂的影响及肾皮质纤溶酶原激活物抑制物1(PAI-1)表达的作用。
3) plasminogen activator inhibitor
纤溶酶原激活物抑制物
1.
Objective To observe the influence of Shenluotong on the protein expression of plasminogen activator inhibitor 1(PAI-1) in kidney remaining tissue in rats with kidney failure induced by 5/6 of nephrectomy.
目的观察肾络通对5/6肾切除肾衰竭大鼠残余肾组织纤溶酶原激活物抑制物-1(PAI-1)蛋白表达的影响。
2.
The activities of tissue plasminogen activator(tPA),plasminogen activator inhibitor(PAI) and plasminogen(PLG) in plasma were determined by chromogenic substrate assay,and thrombi weight was measured.
先给大鼠喂药后以FeCl3诱导左侧颈总动脉血栓形成,以发色底物法测定血浆组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物(PAI)和纤溶酶原(PLG)活性,并测定血栓质量。
3.
Objective To investigate the changes of serum plasminogen activator inhibitor(PAI),D-dimer and thrombomodulin(TM),and the relationship between these changes and phlegm syndrome or blood-stasis syndrome in patients with acute cerebral infarction.
目的探讨急性脑梗死患者血浆纤溶酶原激活物抑制物(PAI)、D-二聚体、血栓调节蛋白(TM)变化与中医痰证、血瘀证变化的关系。
4) Plasminogen activator inhibitor 1
纤溶酶原激活物抑制物
1.
Objective To study the changes of tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and soluble thrombomodulin (sTM) induced by dengue 2 virus (D 2V) infection of vascular endothelial cells.
方法 应用D2 V感染生长良好的第2、3代脐静脉内皮细胞以观察内皮细胞在表达组织纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物1(PAI 1)、凝血酶调节蛋白(TM)等分子变化。
5) plasminogen activator inhibitor type-2
纤溶酶原激活剂抑制物2型
6) PAI-2 (plasminogen activator inhibitor type 2)
PAI-2(纤溶酶原激活剂抑制物二型)
补充资料：血纤维蛋白溶酶原激活剂
血纤维蛋白溶酶原激活剂plasminogen activator
血纤维蛋白溶酶原激活剂plasminogen activator 这是来自指血纤维蛋白溶酶原激活剂原的活性型．但也用作为具有使不活性的血纤维蛋白溶酶原变成有活性的血纤维蛋白溶酶的物质之总称．后者．在生理上可分为组织的（心脏、肺、前列腺、副肾、子宫等组织的激活剂）、血液的（白血球、血小板等激活剂）和体液的物质（尿的尿激酶、来自乳汁、唾液等激活剂）．在牛等动物中，作为血纤维蛋白溶酶原激活剂的前体物质是激活剂原（proactivator），这些激活剂原通过链激酶和溶解激酶（lysokinase）的作用，活化成为血纤维蛋白溶酶原激活剂。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条